Posts tagged ‘Adcetris Mechanism of Action’
December 20th, 2011
The 2011 American Society of Hematology (ASH) annual meeting recently took place in San Diego.
What was hot at ASH in 2011?
In her pre-conference post, Sally Church on Pharma Strategy Blog outlined what she thought would be hot news and interesting data at ASH in 2011.
Amongst the topics she selected were:
- CML: updated phase II PACE trial results for ponatinib
- Myelofibrosis: updated phase III data from COMFORT-1 trial of ruxolitinib
- Myeloma: 5 year data from VISTA trial that compares the combination of Velcade, melphalan and prednisone (VMP) with melphalan and prednisone (MP) alone
- Lymphoma: the CD20 antibody obinutuzumab (GA101).
Sally also mentioned in her pre-conference post a few other compounds likely to be interesting in lymphomas such as the Bruton’s Tyrosine Kinase Inhibitor PCI-32765 (Pharmacyclics) and the aurora kinase A inhibitor, alisertib (Seattle Genetics).
What were your predictions pre-ASH 2011?
It’s not easy to analyze a conference program that contains over 4000+ posters and predict what is going to be a hot topic, and commit to this in public in advance!
To do so requires an understanding of new products in development, mechanisms of action, prior clinical trial results and the impact positive or negative data may have on the standard of care.
If you went to ASH 2011 – how do you think Sally’s predictions stacked up? Sally will be writing her own retrospective assessment in due course.
Although the San Diego weather was much wetter and cooler than expected, there was a lot of interesting data presented at ASH this year that more than made up for it.
Review #ASH11 Twitter Coverage
If you want to read what others thought was hot during the meeting, the #ASH11 tweets have been aggregated on Pharma Strategy Blog.